Published Date: 16 Sep 2024
Data support that ICI rechallenge should be discouraged in patients with advanced RCC
Read Full NewsTake 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 9, 2026.
A review of clinical trial and real-world data found no evidence that oral anticoagulants increase brain imaging abnormalities in patients treated with lecanemab or donanemab for early Alzheimer disease.
Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, provided an outlook on the 2026 MDA meeting and what clinicians should look forward to in preparation.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on epilepsy comorbidities!
Phase 3 Trial Supports Subcutaneous Anifrolumab in Systemic Lupus Erythematosus
5 Pulmonology Headlines You Missed in December 2025
Low Exercise Tolerance Before Kidney Transplant Signals Poor Muscle Recovery
1.
Mindfulness-based interventions are advised by cancer organizations to treat patients' anxiety and depression.
2.
Scientists pioneer noninvasive 3D imaging to enhance skin cancer management
3.
Researchers identify a novel biomarker linked to renal cancer recurrence
4.
FDA Investigating Blood Cancer Risk With Gene Therapy Skysona
5.
Screening tests that are non-invasive show promise in detecting colorectal cancer.
1.
Cemiplimab: A Revolutionary Drug For Treating Cancer
2.
Mechanisms, Efficacy, and Survival Outcomes in AML, Squamous Cell Carcinoma, & Non-Hodgkin Lymphoma
3.
Unlocking the Potential of CPK Levels: How to Maximize Your Health Benefits
4.
Exploring The Science Of Hematopoietic Stem Cell Transplantation: What You Need To Know
5.
Can We Repurpose BV-CHP for Better Outcomes in Peripheral T-Cell Lymphoma?
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
2.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
3.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
4.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation